

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS



**Camurus AB**  
Ideon Science Park  
SE-223 70 Lund, Sweden  
www.camurus.com  
Phone: +46 46 286 57 30

## Press release

# Exercise of the over-allotment option in the initial public offering of Camurus

**Lund — 10 December 2015 — Further to the announcement by Camurus AB (publ) ("Camurus" or "Company") on 3 December 2015, Camurus today confirms that, in connection with the initial public offering and listing of its shares on Nasdaq Stockholm (the "Offering"), Carnegie and Handelsbanken Capital Markets (the "Joint Global Coordinators") have exercised the over-allotment option in full in respect of 1,671,383 existing shares in Camurus.**

In connection with the Offering, the Company's main shareholder Sandberg Development AB ("Sandberg Development") granted the Joint Global Coordinators the option to purchase up to 1,671,383 existing shares of the Company for the purpose of covering over-allotments of shares in the Offering (the "Over-allotment Option"). The Joint Global Coordinators have today exercised the Over-allotment Option in full.

After the exercise of the Over-allotment option, Sandberg Development will hold 20,014,978 shares in Camurus, corresponding to approximately 54 percent of the shares and votes in the Company.

No price stabilization activities have been carried out since the listing, and due to the Company's share price performance, the Joint Global Coordinators have decided to end the stabilization period.

### **About Camurus**

*Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit [www.camurus.com](http://www.camurus.com).*

**NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS**



**For more information**

Fredrik Tiberg, CEO and Head of Research

Tel. +46 (0)46 286 46 92

[fredrik.tiberg@camurus.com](mailto:fredrik.tiberg@camurus.com)

Rein Piir, VP Investor Relations

Tel. +46 (0)70 853 72 92

[ir@camurus.com](mailto:ir@camurus.com)

**Important information**

This press release may not be distributed in or into the United States, Canada, Japan, Australia or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements.

In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the "Prospectus Directive"), this press release is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This press release and the information contained herein are not for distribution in or into the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any offering of securities mentioned herein in the United States will be made only to a limited number of investors who are deemed to be qualified institutional buyers as defined in Rule 144A under the Securities Act ("QIBs") or pursuant to another available exemption from, or transaction not subject to, the registration requirements under the Securities Act.

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this press release relates is available only to, and will be engaged in only with, "qualified investors" (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

**NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS**



This press release may contain forward-looking statements which reflect Camurus' current view on future events and financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

A prospectus prepared in accordance with the Prospectus Directive was published on 19 November 2015 and is, subject to certain restrictions, available on the websites of Camurus ([www.camurus.se](http://www.camurus.se)), Carnegie ([www.carnegie.se](http://www.carnegie.se)) and Handelsbanken ([www.handelsbanken.se/investeringserbjudande](http://www.handelsbanken.se/investeringserbjudande)).

The information in this press release is disclosed by Camurus AB in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 07.00 a.m. on 10 December 2015.